AG Wüllner receives grant for research on new medications for spinocerebellar ataxias

Dr. Laura de Boni, member of the AG Wüllner, received the 10,000 € Novartis Grant of the Foundation for Therapeutic Research for her innovative research on new therapeutic concepts for spinocerebellar ataxias (SCA). The aim of the study is finding new active substances that can directly reduce the number of harmful mutated proteins building up in the neurons of SCA patients to eventually create a new medication. This is an essential approach since up to now a causal treatment of this hereditary neurodegenerative disease still is not possible.